EPHA2, a promising therapeutic target for hepatocellular carcinoma

被引：7
|
作者：
Wang, Hao
Qiu, Wei [1 ]
机构：
[1] Loyola Univ Chicago, Stritch Sch Med, Dept Surg, Maywood, IL 60153 USA
来源：
MOLECULAR & CELLULAR ONCOLOGY | 2021年 / 8卷 / 03期
基金：
美国国家卫生研究院;
关键词：
EPHA2; HCC; AKT; STAT3; JAK1; INHIBITION; RECEPTOR; LIGAND;
D O I：
10.1080/23723556.2021.1910009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Identifying critical drivers of oncogenesis and tumor progression is essential for developing effective hepatocellular carcinoma (HCC) therapeutics. Our recent findings has demonstrated that targeting Ephrin Receptor A2 (EPHA2) suppresses HCC initiation and progression by dual inhibition of the Protein Kinase B (AKT) and Signal Transducer and Activator of Transcription 3 (STAT3) signaling.
引用
收藏
页数：3
相关论文
共 50 条
  • [1] EphA2: A promising therapeutic target in breast cancer
    Ping Zhao
    Dewei Jiang
    Yunchao Huang
    Ceshi Chen
    Journal of Genetics and Genomics, 2021, 48 (04) : 261 - 267
  • [2] EphA2: A promising therapeutic target in breast cancer
    Zhao, Ping
    Jiang, Dewei
    Huang, Yunchao
    Chen, Ceshi
    JOURNAL OF GENETICS AND GENOMICS, 2021, 48 (04) : 261 - 267
  • [3] Quantitative phosphoproteomic analysis identifies the potential therapeutic target EphA2 for overcoming sorafenib resistance in hepatocellular carcinoma cells
    Chen, Chih-Ta
    Liao, Li-Zhu
    Lu, Ching-Hui
    Huang, Yung-Hsuan
    Lin, Yu-Kie
    Lin, Jung-Hsin
    Chow, Lu-Ping
    EXPERIMENTAL AND MOLECULAR MEDICINE, 2020, 52 (03): : 497 - 513
  • [4] Quantitative phosphoproteomic analysis identifies the potential therapeutic target EphA2 for overcoming sorafenib resistance in hepatocellular carcinoma cells
    Chih-Ta Chen
    Li-Zhu Liao
    Ching-Hui Lu
    Yung-Hsuan Huang
    Yu-Kie Lin
    Jung-Hsin Lin
    Lu-Ping Chow
    Experimental & Molecular Medicine, 2020, 52 : 497 - 513
  • [5] EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics
    Ireton, RC
    Chen, J
    CURRENT CANCER DRUG TARGETS, 2005, 5 (03) : 149 - 157
  • [6] EPHA2 Receptor as a Possible Therapeutic Target in Viral Infections
    Vincenzi, Marian
    Mercurio, Flavia Anna
    Leone, Marilisa
    CURRENT MEDICINAL CHEMISTRY, 2024, 31 (35) : 5670 - 5701
  • [7] TARGETING EphA2 SUPPRESSES HEPATOCELLULAR CARCINOMA INITIATION AND PROGRESSION
    Qiu, Wei
    HEPATOLOGY, 2020, 72 : 672A - 672A
  • [8] EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
    Miao, Benchun
    Ji, Zhenyu
    Tan, Li
    Taylor, Michael
    Zhang, Jianming
    Choi, Hwan Geun
    Frederick, Dennie T.
    Kumar, Raj
    Wargo, Jennifer A.
    Flaherty, Keith T.
    Gray, Nathanael S.
    Tsao, Hensin
    CANCER DISCOVERY, 2015, 5 (03) : 274 - 287
  • [9] Gankyrin: a novel promising therapeutic target for hepatocellular carcinoma
    Zamani, Parvin
    Riahi, Maryam Matbou
    Momtazi-Borojeni, Amir Abbas
    Jamialahmadi, Khadijeh
    ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, 2018, 46 (07) : 1301 - 1313
  • [10] EphA2 receptor represents a new marker and therapeutic target in pediatric malignancies
    Couture, D
    Wykosky, J
    Gibo, DM
    Debinski, W
    NEUROSURGERY, 2005, 57 (02) : 418 - 419
12345